1. Special K goes legit

Janssen announced that an antidepressant medication, Esketamine, has been granted Breakthrough Therapy Designation by the FDA. If approved, Esketamine would be used to treat major depressive disorder with imminent risk for suicide, and would be the first new treatment of its kind in the last half-century. Not-so-depressed party-goers have known the drug for a while as “Special K” or something causing an out-of-body experience. Janssen’s Phase II data from May 2016 show that the drug could be on track to create a more positive (and legal) reputation, providing care for a condition that currently has no approved treatment.